Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02955459 · ClinicalTrials.gov registry record · Phase 1
VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers
A Phase 1 study, sponsored by Venatorx Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT02955459: Completed Phase 1 study, sponsored by Venatorx Pharmaceuticals.
NCT02955459 is a Phase 1 study that has completed, run by Venatorx Pharmaceuticals. The registered enrollment target is 84 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02955459, a Phase 1 study, has completed, sponsored by Venatorx Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
This is a 2-part, first-in-human dose-ranging study to evaluate the safety, tolerability and pharmacokinetics of escalating doses of VNRX-5133 administered via intravenous (IV) infusion in healthy subjects. In part 1, subjects will receive a single dose of VNRX-5133; in part 2 subjects will receive VNRX-5133 for 7 days.
Interventions
- DRUG Placebo
- DRUG VNRX-5133
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2016-11 |
| Est. Completion | 2017-06 |
| Phase | Phase 1 |
What the finished NCT02955459 record still lists
NCT02955459 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02955459 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02955459 about?
NCT02955459 is a clinical study titled "VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers". This is a 2-part, first-in-human dose-ranging study to evaluate the safety, tolerability and pharmacokinetics of escalating doses of VNRX-5133 administered via intravenous (IV) infusion in healthy subjects. In part 1, subjects will receive a single dose of VNRX-5133; in part 2 subjects will receive ...
What is the current status of trial NCT02955459?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2016-11. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02955459?
The interventions under investigation include: Placebo (DRUG), VNRX-5133 (DRUG).
Who is sponsoring clinical trial NCT02955459?
This trial is sponsored by Venatorx Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02955459's enrollment target sits among peer trials
84 659th of 2000 higher than 1,336 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia